Kobiolabs
Latest round
- Series B
Last raised
- Jul 2017
Total raised
- $8.7M
Investors
- 3
About Kobiolabs
Founded in 2014 and based in Seoul, South Korea, Kobiolabs is a biotechnology company that focuses on developing microbiome therapeutics for immune, metabolic and neurological. The diff infection program, atopic dermatitis program, and chronic kidney disease program are selected as the government-sponsored project in 2017. The candidate drug for psoriasis, KBLP-001 phases 1 study HREC approve in 2019, and phase 1 study completed in May 2020. The candidate drug for Inflammatory Bowel Disease (IBD) was initiated in April 2020 and received phase two study approval from the US in July 2021. The company was listed on the KOSDAQ stock market in November 2020. The company engages in microbiome therapeutics for immune, metabolic and neurological. The new drug development pipeline has entered clinical phases including candidates for drugs for psoriasis, asthma, and IBD. And the candidate's drugs for immune-oncology, liver disease, autism spectrum disorder non-alcoholic steatohepatitis are in the development phase.
Who invested in Kobiolabs
3 investors across 1 round
See all investors in Kobiolabs
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jul 7, 2017
Amount
$8.7M
Investors
Questions about Kobiolabs
Who invested in Kobiolabs?
Kobiolabs has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kobiolabs raised?
Kobiolabs has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Kobiolabs last raise money?
Kobiolabs's most recent round on record is a Series B, in Jul 2017.
What does Kobiolabs do?
Founded in 2014 and based in Seoul, South Korea, Kobiolabs is a biotechnology company that focuses on developing microbiome therapeutics for immune, metabolic and neurological.
Where is Kobiolabs headquartered?
Kobiolabs is headquartered in Seoul, South Korea.
Which VCs invest in companies like Kobiolabs?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Kobiolabs's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Kobiolabs? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.